SecBot SecBot

MDGL drug pipeline

$427.39
+0.5% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.0%
1-day, median of 1 event
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
1
0 with results posted

Upcoming catalysts

1 dated
  1. Dec 2026
    Resmetirom
    Phase 3 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketUnknown — Phase 1 dosing only began June 2026; Phase 2 anticipated 2027, so approval (if trials succeed) is realistically many years away (early-to-mid 2030s).

MGL-2086 Updated Aug 2

What to watch

Do not trade MDGL on MGL-2086, there is no dated readout to trade; near-term price action will be driven by Rezdiffra's commercial ramp and the 2027 MAESTRO F4c cirrhosis outcomes readout. Watch for (1) any early Phase 1 SAD/MAD data release for MGL-2086 (likely 2027), (2) FDA feedback on the Rezdiffra/MGL-2086 Phase 2 combo design, and (3) progress of rival oral GLP-1s (notably Lilly's orforglipron, the molecule this is derived from), which caps the strategic upside.

Bull case
  • Combining an oral GLP-1 with Rezdiffra could yield a once-daily, best-in-disease oral pill for MASH, Madrigal explicitly frames it that way, and a Phase 2 combo study with resmetirom is planned for 2027.
  • Cheap optionality: exclusive global rights cost just $120M upfront (up to $2B in milestones plus royalties), and the mechanism is validated by the huge GLP-1 class, reducing mechanism risk.
  • Execution is on schedule: Phase 1 SAD dosing initiated June 2026 as planned, and SAD/MAD data are expected to inform the Phase 2 design.
Bear case
  • No clinical data yet, dosing only began June 2026; tolerability and efficacy of an oral GLP-1 specifically in MASH patients are unproven, and most early-stage GLP-1 programs never reach market.
  • Brutal competition: MGL-2086 is an orforglipron derivative, and Lilly's orforglipron itself is far ahead in late-stage trials, while Novo's oral semaglutide is already approved, MGL-2086 would be a late entrant in a crowded oral-GLP-1 race.
  • Long, expensive, risky road: Phase 2 anticipated 2027 at earliest, approval many years away, with up to $2B in milestone and royalty obligations owed to CSPC; Madrigal also booked a ~$117M one-time R&D charge for the license in Q3 2025.

Other drugs in filings and trials

no drug report yet
  • REZDIFFRA Last: Approval · Mar 14, 2024
  • MGL-3196 (resmetirom) 1 trial
  • Resmetirom 1 trial

Past FDA events & how the stock moved

1 events
DateDrugEvent1 day5 days
Mar 14, 2024REZDIFFRAApproval−1.0%−6.5%

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
ResmetiromA Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)Phase 3Active not recruiting845Dec 2026
MGL-3196 (resmetirom)Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)Phase 2Completed · results116Jan 15, 2018